TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31477542
Drug: Standard rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rTMS (5 daily sessions per week for 4 weeks)
Study: 27455886
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (MTX) 7.5 mg twice or thrice weekly
Study: 27455886
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (MTX) 15 mg or 22.5 mg in a single dose weekly
Study: 27455886
Drug: Parenteral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Parenteral Methotrexate (MTX) 15 mg or 22.5 mg in a single dose weekly
Study: 26354605
Drug: Sake yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sake yeast supplementation (500 mg of sake yeast powder)
Study: 26564511
Drug: Conventional clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional clinical treatment evaluations
Study: 17067330
Drug: Stimulating catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulating catheter with 100-ml bags of ropivacaine 2 mg/ml
Study: 17067330
Drug: Conventional catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional catheter with 100-ml bags of ropivacaine 2 mg/ml
Study: 17067330
Drug: Stimulating catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulating catheter with 200-ml bags of ropivacaine 2 mg/ml
Study: 17067330
Drug: Conventional catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional catheter with 200-ml bags of ropivacaine 2 mg/ml
Study: 9164208
Drug: Paclitaxel 250
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 250 mg/m2
Study: 12807937
Drug: Paclitaxel 250
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 250 mg/m2 with filgrastim 5 microg/kg
Study: 12807937
Drug: Paclitaxel 250
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 250 mg/m2 with filgrastim 10 microg/kg
Study: 12807937
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 without filgrastim
Study: 9192506
Drug: Reduced training
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced training (one weekly session for 6 months)
Study: 3069479
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg chlorambucil
Study: 3069479
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg chlorambucil
Study: 3069479
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg chlorambucil
Study: 3069479
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg chlorambucil
Study: 3069479
Drug: Dose-corrected AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-corrected AUC for chlorambucil
Study: 3069479
Drug: Dose-corrected AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-corrected AUC for metabolite
Study: 31008545
Drug: 0.9 g
Normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g MMT/kg
Study: 31008545
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g MMT/kg
Study: 31008545
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g MMT/kg
Study: 31008545
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g MMT/kg
Study: 28783464
Drug: MLS laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLS laser therapy and exercises
Study: 28783464
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy plus exercises (PL + EX)
Study: 25217123
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg i.v.)
Study: 23042808
Drug: CBD 600
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD 600 mg
Study: 17438314
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (40 mg of pantoprazole, 1 g of amoxicillin, and placebo for the first 5 days, followed by 40 mg of pantoprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Study: 17438314
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (40 mg of pantoprazole, 500 mg of clarithromycin, and 1 g of amoxicillin, each administered twice daily for 10 days)
Study: 15627534
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of naloxone (1.2 mg over 48 h) and morphine (6 mg over 48 h) in 0.1% bupivacaine
Study: 15627534
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural morphine (6 mg over 48 h) in 0.1% bupivacaine
Study: 1099172
Drug: Apomorphine HCl
Normalized name: apomorphine HCl
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine HCl (1 mg) administered subcutaneously three times a day for 14 days
Study: 1099172
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (placebo) administered subcutaneously three times a day for 14 days
Study: 28952295
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanate potassium
Study: 21566113
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium thiosulfate (STS)
Study: 21566113
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium thiosulfate (STS)
Study: 16549458
Drug: L-[1-(13C)]-leucine oxidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[1-(13C)]-leucine oxidation measured after a primed, continuous oral administration of the tracer in the postabsorptive state
Study: 16549458
Drug: L-[1-(13C)]-leucine oxidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[1-(13C)]-leucine oxidation measured after a primed, continuous oral administration of the tracer in the fed state
Study: 9327194
Drug: rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifaximin 400 mg three times daily
Study: 9327194
Drug: neomycin 1
Normalized name: neomycin 1 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: neomycin 1 g three times daily
Study: 20863008
Drug: Ritodrine hydrochloride
Normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine hydrochloride 10 mg p.o.
Study: 20863008
Drug: Ritodrine hydrochloride
Normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine hydrochloride 20 mg p.o.
Study: 20863008
Drug: Ritodrine hydrochloride
Normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine hydrochloride 30 mg p.o.
Study: 20863008
Drug: Ritodrine hydrochloride
Normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine hydrochloride 10 mg i.m.
Study: 10483821
Drug: Ondansetron 24
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 24 mg q.d.
Study: 10483821
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg b.i.d.
Study: 10483821
Drug: Ondansetron 32
Normalized name: ondansetron 32 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 32 mg q.d.
Study: 8694672
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of intramuscular ketorolac tromethamine
Study: 8694672
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of intravenous chlorpromazine hydrochloride
Study: 1928881
Drug: Hydrocodone/acetaminophen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen (5 mg hydrocodone with 500 mg acetaminophen)
Study: 1928881
Drug: Codeine/acetaminophen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/acetaminophen (30 mg codeine with 500 mg acetaminophen)
Study: 7154835
Drug: Naloxone (NLX)
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone (NLX) 0.4 mg i.v.
Study: 21284552
Drug: Crestal implant
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal implant placement
Study: 21284552
Drug: Crestal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal and Subcrestal implant placement
Study: 20228003
Drug: MgSO₄ 6.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO₄ 6.4% (2.5 mL) administered in 3 nebulisations at 30 minute intervals
Study: 17872451
Drug: Nateglinide (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (270 mg/dL)
Study: 9164228
Drug: Oral dolasetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dolasetron 200 mg and oral dexamethasone 20 mg (one-dose regimen)
Study: 9164228
Drug: Oral dolasetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dolasetron 200 mg and oral dexamethasone 20 mg (two-dose regimen)
Study: 9164228
Drug: One-dose regimen
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose regimen
Study: 10515287
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg)
Study: 7957541
Drug: Cholestyramine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (16 g)
Study: 7957541
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg combined with cholestyramine (4 g)
Study: 7957541
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg combined with cholestyramine (8 g)
Study: 7957541
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg combined with cholestyramine (16 g)
Study: 7957541
Drug: Fluvastatin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin and Cholestyramine (all doses)
Study: 3608372
Drug: Citrate administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate administration (5 mmol of calcium chloride and 21 mmol of citrate in the form of sodium potassium citrate)
Study: 26794937
Drug: Convers Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convers Plus 4/1.25 mg Tablet (test)
Study: 26794937
Drug: Bipreterax 4/1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipreterax 4/1.25 mg Tablet (reference)
Study: 25886226
Drug: Granisetron (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (2 mg)
Study: 16227761
Drug: Telmisartan 40-80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40-80 mg daily plus hydrochlorothiazide 12.5 mg daily (if needed)
Study: 11953670
Drug: Erythropoietin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin therapy (epoetin-alpha)
Study: 10441604
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Phenobarbital first)
Study: 10441604
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Phenytoin first)
Study: 3066139
Drug: Nimodipine 2
Normalized name: Nimodipine 200 microgram/mL solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 2 mg/h
Study: 3066139
Drug: Nimodipine 3
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 3 mg/h
Study: 2181334
Drug: Nimodipine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (both doses) in patients with Hunt and Hess grades IV or V
Study: 2181334
Drug: Nimodipine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (both doses) in patients with Hunt and Hess grades I to III
Study: 473853
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Metoprolol
Study: 473853
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Pindolol
Study: 27864127
Drug: latiglutenase 100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: latiglutenase 100, 300, 450, 600, or 900 mg daily for 12 or 24 weeks
Study: 12467956
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution swallowed (0, 5, 10, 20, and 40%)
Study: 12467956
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution spit (0, 5, 10, 20, and 40%)
Study: 12467956
Drug: Fear to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fear to swallow sucrose solution (covariate)
Study: 7840322
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplements
Study: 2206140
Drug: Alpha‐tocopherol‐enriched coconut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha‐tocopherol‐enriched coconut oil supplements (placebo)
Study: 7227621
Drug: Prothiaden (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothiaden (75 mg)
Study: 7227621
Drug: Lentizol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentizol (50 mg)
Study: 25953494
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave therapy (ESWT)
Study: 7553070
Drug: injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: injections of allergen-specific antibody complexes
Study: 2187982
Drug: Exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise plus relaxation and breathing therapy (Treatment A)
Study: 2187982
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training only (Treatment B)
Study: 31498113
Drug: 12-month DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month DAPT followed by 12-month aspirin monotherapy (control)
Study: 27583931
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (Group C)
Study: 27583931
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with hypertension (Group D)
Study: 23225838
Drug: Carbamazepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (100 mg, 3 times a day for 60 days) + Botulinum toxin A (local intramuscular injections)
Study: 23225838
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (local intramuscular injections only)
Study: 12502011
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg mirtazapine
Study: 2562333
Drug: Omeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (10 mg or 20 mg each morning for 2 weeks)
Study: 2562333
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice daily for 2 weeks)
Study: 2562333
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg nightly for 1 year)
Study: 1179368
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with chemotherapy
Study: 29858027
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg/day)
Study: 29858027
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) and Bevacizumab (7.5 mg/kg) every 21 days
Study: 27250219
Drug: Beauty care
Normalized name: ALCOHOL 60.15 mL in 100 mL TOPICAL GEL [Henkel Beauty Care Professional]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beauty care program (two training sessions per month for 3 months and daily facial skin care)
Study: 24184299
Drug: Synbiotic supplement
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplement for eight weeks
Study: 18520184
Drug: Endolymphatic sac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endolymphatic sac drainage and steroid instillation (G-I)
Study: 18520184
Drug: Endolymphatic sac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endolymphatic sac drainage without steroid instillation (G-II)
Study: 18520184
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (G-III)
Study: 10725767
Drug: DHA supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplement (200 mg DHA/day)
Study: 10725767
Drug: (13)C-labeled linoleic
Normalized name: linoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: (13)C-labeled linoleic acid (1 mg/kg body weight)
Study: 8542857
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine-adrenaline before starting surgery and a booster dose after 60 min
Study: 8542857
Drug: Epidural dose
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural dose of bupivacaine-adrenaline at 60 min
Study: 1781803
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg with glycine 250 mg
Study: 1781803
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg without glycine
Study: 6168829
Drug: Prenalterol (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (0.1, 0.25, and 0.5 mg)
Study: 6168829
Drug: Prenalterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (10 times higher dose after beta-blockers)
Study: 6168829
Drug: Metoprolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (20 mg)
Study: 22192847
Drug: MF59-H5N1 vaccine
Normalized name: influenza A virus (H5N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-H5N1 vaccine
Study: 22867771
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump therapy (SAPT)
Study: 18984887
Drug: 12-week buprenorphine-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week buprenorphine-naloxone (up to 24 mg per day for 9 weeks, then tapered to week 12)
Study: 18984887
Drug: Detox group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detox group (14-day taper, up to 14 mg per day)
Study: 15974485
Drug: Gui‐zhi‐fu‐ling‐wan (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gui‐zhi‐fu‐ling‐wan (herbal therapy)
Study: 27307358
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (IV administration of 15 mg/kg of TXA combined with topical administration of 1 g/100 mL of TXA)
Study: 27307358
Drug: Single IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV group (IV administration of 15 mg/kg of TXA)
Study: 14687987
Drug: IFN-alpha maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha maintenance therapy (41 patients)
Study: 11151453
Drug: Trastuzumab as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab as a single agent
Study: 25557693
Drug: Test meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test meal (240 mL, 12 kcal broth)
Study: 17473091
Drug: Head cooling
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head cooling for 72 hours, starting within 6 hours after birth (rectal temperature maintained at 34.5 +/- 0.5 degrees C)
Study: 1091397
Drug: 0.5‐mg doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐mg doses of digoxin from lot 1
Study: 1091397
Drug: 0.5‐mg doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐mg doses of digoxin from lot 2
Study: 1091397
Drug: 0.5‐mg doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐mg doses of digoxin from lot 3
Study: 1091397
Drug: 0.5‐mg doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐mg doses of digoxin from lot 4
Study: 1091397
Drug: 0.5‐mg doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐mg doses of digoxin from one lot taken twice
Study: 31378395
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (500 mg twice a day, adjustable to a maximum of four tablets and a minimum of one tablet a day)
Study: 31378395
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two oral tablets a day)
Study: 28514344
Drug: Erbium laser
Normalized name: erbium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erbium laser treatment
Study: 23975856
Drug: Conventional surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional surgical treatment (Control)
Study: 17723882
Drug: Serum IL-15
Normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum IL-15 levels less than 3.0 pg/mL
Study: 17723882
Drug: Serum IL-15
Normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum IL-15 levels between 3.0-5.3 pg/mL
Study: 17723882
Drug: Serum IL-15
Normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum IL-15 levels greater than or equal to 5.3 pg/mL
Study: 17723882
Drug: Serum IL-15
Normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum IL-15 levels less than 5.5 pg/mL
Study: 17723882
Drug: Serum IL-15
Normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum IL-15 levels between 5.5-9.0 pg/mL
Study: 17723882
Drug: Serum IL-15
Normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum IL-15 levels greater than or equal to 9.0 pg/mL